March 3, 2015
Appointment Of New Director
February 16, 2015
MBI Closes Shares For Debt Transaction
February 3, 2015
Med BioGene Provide Shareholders Update
January 13, 2015
MBI Announces Shares For Debt Transaction
November 30, 2014
October 02, 2014
Status Update Precision Therapeutics Inc. to Med Biogene Inc.
October 01, 2014
Closing of Private Placement
September 05, 2014
Directors Nominated By Dissident Shareholder Elected At Annual General Meeting
September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 29, 2014
Med BioGene Reports Financial Results for Q2 2014
August 21, 2014
Med BioGene Responds to Assertions Made by Dissident Shareholder
August 15, 2014
Med BioGene Provides Update and Announces Proposed Financing
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
March 24, 2014
Med BioGene Announces Regulatory Approval of GeneFx® Lung
Welcome to Med BioGene
Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests.
Med BioGene’s lead test under development is GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC) who, following surgical removal of their tumor, are at higher and lower risks of mortality. In an initial study of patient specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, published in the Journal of Clinical Oncology, patients classified by GeneFx Lung as higher risk benefited from adjuvant chemotherapy, and those classified as lower risk did not benefit and may have experienced a detrimental effect from adjuvant chemotherapy. GeneFx Lung was subsequently validated in predicting patient mortality in four independent studies involving data from tumor specimens totaling 676 untreated early-stage NSCLC patients. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy.
On April 15, 2011, Precision Therapeutics, Inc. and Med BioGene closed their commercialization agreement. The agreement provides to Precision exclusive global rights to develop and commercialize GeneFx Lung.
For more information on Precision Therapeutics, please see www.precisiontherapeutics.com.
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer